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A man in his 70s was referred to our hospital for further examination of a positive occult blood finding. 
Imaging studies showed that the patient had right renal pelvic cancer with interaortocaval, multiple paracaval 
and left supraclavicular lymph node metastases (cT3N2Ml). Induction chemotherapy was performed with 
5 cycles of MEC (methotrexate/ epirubicin/ cisplatin) followed by 2 cycles of GT (gemcitabine/paclitaxel). 
After the combined chemotherapies, the residual lesions were the prima町 tumorin the right renal pelvis and 
the left supraclavicular lymph node. Right total nephroureterectomy combined with lymph node dissection 
of paraaortic, paracaval, and interaortocaval area and left cervical area were performed. Histopath-
ologically血epostoperative T stage of the primarγtumor was determined as ypT3. As for配 lymphnodes 
dissected, an interaortocaval lymph node alone, but not the other nodes, contained viable cancer cels. 
Adjuvant chemotherapy was performed with 7 courses of GT therapy. The patient had intravesical 
recurrence once and received transurethral resection of bladder tumor followed by intravesical instillations of 
Bacillus Calmette-G田 rin(BCG). Finally, the patient has been free from recurrence for 10 years after the 
final treatment. 
(Hinyokika Kiyo 65: 13-17, 2019 DOI: 10.14989/ ActaUroUap_65_1_13) 























触知した.Eastern Cooperative Oncology Group Per-
formance Status (ECOGPS）は Oであった．
検査所見：
血液生化学： WBC7, 800/ μl, RBC 508万／μI, Hb 
15. 0 g/dl, Pit 22万IμI, BUN 19 mg/di, Cre 1. 1 mg/ 
di, CRP 0.3 mg/di 
腫蕩マーカー： CEA4. 5 ng/ml, CAl9-9 1. O> IU/ 
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ml, CYFRA 10.4ng/ml 








Fig. 1. An enhanced ceivical-chest-abdominal CT 
showed件）a mass in the right renal pelvis 
which infiltrated the renal parenchyma, (B) 
a slightly swelling interaortocaval lymph 
node (12×8mm, white a打ow)(C) and a left 
supracla吋cularenlarged lymph node (23× 
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Fig. 2. (A) An FDG-PET image showed increased FDG uptake in an interaortocaval lymph node (white arrowめ，
paracaval lymph nodes (black arrows) and a left supraclavicular lymph node (white arrow head). (B) An FDG司































































Fig. 3. An enhanced cervical-chest-abdominal CT 
after 4 courses of MEC therapy. (A) The 
mass diminished about 40% in size (PR). 
(B) The interaortocaval lymph node reduced 
in size markedly (CR, white arrow). (C) 
The left supraclavicular lymph node 
diminished in more than half of the original 







Fig. 4. （判 Macroscopic五ndingsof the re肌 ted
specimen showed the renal pelvic mas, 
which was about 5 cm in diameter. It was 
pa同alyreplaced wi出hemorrhage,necrotic 
tissue and fibrous tisue. (B) Microscopic 
findings of the primary tumor showed inva-
sive urothelial carcinoma, G2 > G3, ypT3, 
lyO, vO, RMO. (C) Hist 
ings of th巴leftsupraclavicular lymph node 
showed pathological complete response and 
fibrosis (white arrow). Hematoxylin-eosi rl
sta凶噌（B）×20,(C)×100. 
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